S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.80 (+0.35%)
AAPL   460.42 (+1.85%)
MSFT   208.68 (-0.24%)
FB   261.07 (+0.45%)
GOOGL   1,517.17 (+0.66%)
AMZN   3,166.45 (+0.13%)
NVDA   458.36 (+0.16%)
CGC   17.33 (+0.46%)
BABA   254.12 (-0.42%)
TSLA   1,624.62 (+4.49%)
GE   6.61 (-1.64%)
MU   46.23 (-4.64%)
AMD   81.98 (-0.76%)
T   29.90 (-0.93%)
F   7.02 (-1.27%)
ACB   10.19 (+3.98%)
GILD   68.18 (-0.96%)
NFLX   481.11 (+1.19%)
DIS   130.96 (-0.63%)
BAC   26.28 (-1.68%)
BA   174.72 (-0.41%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.80 (+0.35%)
AAPL   460.42 (+1.85%)
MSFT   208.68 (-0.24%)
FB   261.07 (+0.45%)
GOOGL   1,517.17 (+0.66%)
AMZN   3,166.45 (+0.13%)
NVDA   458.36 (+0.16%)
CGC   17.33 (+0.46%)
BABA   254.12 (-0.42%)
TSLA   1,624.62 (+4.49%)
GE   6.61 (-1.64%)
MU   46.23 (-4.64%)
AMD   81.98 (-0.76%)
T   29.90 (-0.93%)
F   7.02 (-1.27%)
ACB   10.19 (+3.98%)
GILD   68.18 (-0.96%)
NFLX   481.11 (+1.19%)
DIS   130.96 (-0.63%)
BAC   26.28 (-1.68%)
BA   174.72 (-0.41%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.80 (+0.35%)
AAPL   460.42 (+1.85%)
MSFT   208.68 (-0.24%)
FB   261.07 (+0.45%)
GOOGL   1,517.17 (+0.66%)
AMZN   3,166.45 (+0.13%)
NVDA   458.36 (+0.16%)
CGC   17.33 (+0.46%)
BABA   254.12 (-0.42%)
TSLA   1,624.62 (+4.49%)
GE   6.61 (-1.64%)
MU   46.23 (-4.64%)
AMD   81.98 (-0.76%)
T   29.90 (-0.93%)
F   7.02 (-1.27%)
ACB   10.19 (+3.98%)
GILD   68.18 (-0.96%)
NFLX   481.11 (+1.19%)
DIS   130.96 (-0.63%)
BAC   26.28 (-1.68%)
BA   174.72 (-0.41%)
S&P 500   3,373.43 (-0.20%)
DOW   27,896.72 (-0.29%)
QQQ   272.80 (+0.35%)
AAPL   460.42 (+1.85%)
MSFT   208.68 (-0.24%)
FB   261.07 (+0.45%)
GOOGL   1,517.17 (+0.66%)
AMZN   3,166.45 (+0.13%)
NVDA   458.36 (+0.16%)
CGC   17.33 (+0.46%)
BABA   254.12 (-0.42%)
TSLA   1,624.62 (+4.49%)
GE   6.61 (-1.64%)
MU   46.23 (-4.64%)
AMD   81.98 (-0.76%)
T   29.90 (-0.93%)
F   7.02 (-1.27%)
ACB   10.19 (+3.98%)
GILD   68.18 (-0.96%)
NFLX   481.11 (+1.19%)
DIS   130.96 (-0.63%)
BAC   26.28 (-1.68%)
BA   174.72 (-0.41%)
Log in

LON:TILSTiziana Life Sciences Share Price, Forecast & News

GBX 175
-15.00 (-7.89 %)
(As of 08/13/2020 11:09 AM ET)
Add
Compare
Today's Range
160
Now: GBX 175
180
50-Day Range
99
MA: GBX 155.83
268
52-Week Range
0.98
Now: GBX 175
220
Volume1.93 million shs
Average Volume4,999 shs
Market Capitalization£291.22 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops TZLS-501, a human anti-interleukin-6 receptor monoclonal antibody that is in pre-clinical development. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
Read More
Tiziana Life Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.38 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-74952379

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 0.09 per share
Book ValueGBX (4) per share

Profitability

Miscellaneous

Employees10
Market Cap£291.22 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 175
-15.00 (-7.89 %)
(As of 08/13/2020 11:09 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TILS News and Ratings via Email

Sign-up to receive the latest news and ratings for TILS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tiziana Life Sciences (LON:TILS) Frequently Asked Questions

How has Tiziana Life Sciences' stock price been impacted by Coronavirus (COVID-19)?

Tiziana Life Sciences' stock was trading at GBX 85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TILS stock has increased by 105.9% and is now trading at GBX 175.
View which stocks have been most impacted by COVID-19
.

How were Tiziana Life Sciences' earnings last quarter?

Tiziana Life Sciences PLC (LON:TILS) announced its earnings results on Thursday, June, 18th. The biotechnology company reported ($5.40) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($5.00) by $0.40.
View Tiziana Life Sciences' earnings history
.

Has Tiziana Life Sciences been receiving favorable news coverage?

Press coverage about TILS stock has been trending extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tiziana Life Sciences earned a media sentiment score of -4.1 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.
View the latest news about Tiziana Life Sciences
.

Who are some of Tiziana Life Sciences' key competitors?

What other stocks do shareholders of Tiziana Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Synergy Pharmaceuticals (SGYP), ServiceNow (NOW), Broadcom (AVGO), Dropbox (DBX), Enterprise Products Partners (EPD), Franco Nevada (FNV), Micron Technology (MU), NVIDIA (NVDA), RingCentral (RNG) and Tesla (TSLA).

Who are Tiziana Life Sciences' key executives?

Tiziana Life Sciences' management team includes the following people:
  • Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA, Founder & Exec. Chairman (Age 47)
  • Dr. Kunwar Shailubhai, CEO, Chief Scientific Officer & Exec. Director (Age 61)
  • Dr. Andrea Brancale, Scientific Founder
  • Mr. Richard Clarkson Ph.D., Scientific Founder
  • Mr. Andrew Westwell Ph.D., Scientific Founder

What is Tiziana Life Sciences' stock symbol?

Tiziana Life Sciences trades on the London Stock Exchange (LON) under the ticker symbol "TILS."

How do I buy shares of Tiziana Life Sciences?

Shares of TILS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Tiziana Life Sciences' stock price today?

One share of TILS stock can currently be purchased for approximately GBX 175.

How big of a company is Tiziana Life Sciences?

Tiziana Life Sciences has a market capitalization of £291.22 million. Tiziana Life Sciences employs 10 workers across the globe.

What is Tiziana Life Sciences' official website?

The official website for Tiziana Life Sciences is www.tizianalifesciences.com.

How can I contact Tiziana Life Sciences?

Tiziana Life Sciences' mailing address is 3rd Fl, 11-12 St. James's Square, LONDON, SW1Y 4LB, United Kingdom. The biotechnology company can be reached via phone at +44-20-74952379.

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.